Antisense therapeutics in chronic myeloid leukaemia: The promise, the progress and the problems

Leukemia

Volumn 14, Issue 3, 2000, Pages 347-355

  Clark, R E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antisense oligodeoxyribonucleotides; Chronic myeloid leukaemia

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GENETICS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GENE TARGETING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEIC ACID PROBE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

EID: 0034093722     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401677     Document Type: Review

References (133)

1. Nienhuis AW. Genetic mechanisms in neoplasia. Blood 1984; 64: 949-950.
2. Andersen WF. Human gene therapy. Nature 1998; 392: 25-30.
3. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389: 239-242.
4. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.
5. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F. Clinical application of ribozymes. Lancet 1995; 345: 1027-1031.
6. James HA, Gibson I. The therapeutic potential of ribozymes. Blood 1998; 91: 371-382.
7. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-284.
8. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-1012.
9. Khan IM, Coulson JM. A novel method to stabilise antisense oligonucleotides against exonuclease degradation (published erratum appears in Nucleic Acids Research 21: 4433, 1993). Nucleic Acids Res 1993; 21: 2957-2958.
10. Giles RV, Spiller DG, Tidd DM. Chimaeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anti-Cancer Drug Design 1993; 8: 33-51.
11. Giles RV, Spiller DG, Green JA, Clark RE, Tidd DM. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 1995; 86: 744-754.
12. Wilkinson YA, McKenna PG. The effects of thymidine on deoxyribonucleotide pool level, cytotoxicity and mutation induction in Friend mouse erythroleukaemia cells. Leukemia Res 1989; 13: 615-620.
13. Tanaka Y, Yoshihara K, Tsuyuki M, Kamiya T. Apoptosis induced by adenosine in human leukaemia HL-60 cells. Exp Cell Res 1994; 213: 242-252.
14. Ross DD, Akman SA, Schrecker AW, Bachur NR. Effects of deoxynucleosides on cultured human leukaemia cell growth and deoxynucleotide pools. Cancer Res 1981; 41: 4493-4498.
15. Russell NH, Hoffbrand AV, Bellingham AJ. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thylymphoblasts from human bone marrow. Leukemia Res 1986; 10: 325-329.
16. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific hut non-antisense mechanism. Blood 1995; 86: 3891-3896.
17. Vaerman JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F, Martiat P. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood 1997; 90: 331-339.
18. Vaerman JL, Martiat P. How do antisense oligdeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Blood 1996; 87: 4020.
19. Gao WY, Storm C, Egan W, Cheng YC. Cellular pharmacology of phosphorthioate homooligodeoxynucleotides in human cells. Mol Pharmacol 1993; 43: 45-50.
20. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L. Aptameric inhibition of p210 BCR-ABL tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994; 22: 2150-2154.
21. Bergan R, Kyle E, Connell Y, Neckers L. Inhibition of protein tyrosine kinase activity in intact cells by the aptameric action of oligodeoxyribonucleotides. Antisense Res Dev 1995; 5: 33-38.
22. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. Antisense bcr-abl oligomers cause non-specific inhibition of chronic myeloid leukaemia cell lines. Leukemia 1994; 8: 2156-2162.
23. Miller PS, McParland KB, Jayaraman K, Ts'o POP. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 1981; 20: 1874-1880.
24. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligonucleotides in chronic myelogenous leukemia. Blood 1994; 84: 601-607.
25. Tidd DM, Hawley P, Warenius HM, Gibson I. Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues. Anti-Cancer Drug Design 1988; 3: 117-127.
26. Smetsers TFCM, Linders EHP, van de Locht LTF, de Witte TM, Mensink EJBM. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br J Haematol 1997; 96: 377-381.
27. Giles RV, Spiller DG, Grzybowski J, Clark RE, Nicklin P, Tidd DM. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res 1998; 26: 1567-1575.
28. Giles RV, Tidd DM. Enhanced RNase H activity with methylphosphonodiester phosphodiester chimaeric antisense oligodeoxynucleotides. Anti-Cancer Drug Design 1992; 7: 37-48.
29. Yaswen P, Stampfer M, Ghosh K, Cohen J. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 1993; 3: 67-77.
30. Burgess TL, Fischer EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL. The antiproliterative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-4055.
31. Yamamato S, Yamamato T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment IFN-mediated natural killer activity. J Immunol 1992; 148: 4072-4076.
32. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev 1996; 6: 133-139.
33. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-2122.
34. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxyribonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89: 2994-2998.
35. Tidd DM, Spiller DG, Broughton CM, Clark RE, Giles RV. Oligodeoxynucleotides with a CpG motif induce apoptosis in T lymphocytic leukemia lines. (Submitted).
36. Giles RV, Grzybowski J, Spiller DG, Tidd DM. Enhanced antisense effects resulting from an improved Streptolysin O protocol for oligodeoxynucleoticle delivery into human leukaemia cells. Nucleotides Nucleosides 1997; 16: 1155-1163.
37. Spiller DG, Giles RV, Broughton CM, Grzybowski J, Ruddell CJ, Tidd DM, Clark RE. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analogue mediated biological responses. Antisense Res Dev 1998; 8: 281-293.
38. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 1991; 19: 5543-5550.
39. Tonkinson JL, Stein CA. Patterns of intracellular compartmentalisation, trafficking and acidification of 5′-fluorescein labelled phosphodiester and phosphorothioate oligodeoxyribonucleotides in HL60 cells. Nucleic Acids Res 1994; 22: 4268-4275.
40. Moller P, Johnsen HE, Dahl O. Stability and cellular uptake of phosphorothioate oligodeoxyribonucleotides (PS-ODNs) in human stem cells. Bone Marrow Transplant 1995; 15 (Suppl. 2): S107 (Abstr.).
41. Agrawal S, Temsamini J, Tang JY. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acid Sci USA 1991; 88: 7595-7599.
42. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 1993; 32: 4855-4861.
43. Spiller DG, Tidd DM. The uptake kinetics of chimaeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anticancer Drug Design 1992; 7: 115-129.
44. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA mediated immunisation in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996; 93: 12496-12501.
45. Noonberg SB, Garovoy MR, Hunt CA. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol 1993; 101: 727-731.
46. Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 1994; 103: 569-575.
47. Clark RE. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leuk Lymphoma 1995; 19: 189-195.
48. Bennett CF, Chiang M-Y, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-1033.
49. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 1991; 10: 1111-1118.
50. Boutorin AS, Gus'kova EV, Ivanova EM, Kobetz ND, Zarytova VF, Ryte AS, Yurchenko LV, Vlassov VV. Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazium residues at their 3′-terminus and their interaction with DNA within mammalian cells. FEBS Lett 1989; 254: 129-132.
51. Leonetti J-P, Degols G, Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconj Chem 1990; 1: 149-153.
52. Spiller DG, Giles RV, Grzybowski J, Tidd DM, Clark RE. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukaemia cells: a comparison of Streptolysin-O permeabilisation, electroporation and lipophilic conjugation. Blood 1998; 91: 4738-4746.
53. Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993; 190: 952-960.
54. Ropert C, Lavignon M, Dubemet C, Couvreur P, Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun 1992; 183: 879-885.
55. Clarenc JP, Degols G, Leonetti JP, Milhaud P, LeBleu B. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Design 1993; 8: 81-94.
56. Chavany C, Le Doan T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharma Res 1992; 9: 441-449.
57. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr J-P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
58. Colige A, Sokolov BP, Nugent P, Baserga R, Prockop DJ. Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry 1993; 32: 7-11.
59. Konopleva M, Tari A, Lopez-Berenstein G, Andreef M. Inhibition of BCL-2 with liposomal-delivered antisense oligonucleotides (ASODN) induces apoptosis and increases the sensitivity of primary acute myeloid leukaemia (AML) cells and cell lines to cytosine arabinoside and doxorubicin. Blood 1997; 90 (Suppl. 1): 494a (Abstr.).
60. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996; 88: 731-741.
61. Taj AS, Martiat P, Dhut S, Chaplin TL, Dowding C, Th'ng KH, Goldstein I, Daley CQ, Young BD, Goldman JM. Inhibition of p210 bcr-abl expression in K562 cells by electroporation with antisense oligonucleotides. Leuk Lymphoma 1990; 3: 201-208.
62. Etkin M, Filaccio M, Ellerson D, Suh S, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Moseley AM, Reading C, Khouri I, Talpaz M, Kantarjian H, Deisseroth A. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukaemia patients and from normal individuals. Hum Gene Trier 1992; 3: 137-145.
63. Hughes PF, Thacker JD, Hogge D, Sutherland HJ, Thomas TE, Lansdorp PM, Eaves CJ, Humphries RK. Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. J Clin Invest 1992; 89: 1817-1824.
64. BCR-ABI expression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 1993; 81: 502-509.
65. Cornetta K, Moore A, Leemhuis T, Moen RC, Tricot G, Leibowitz D, Hoffman R. Retroviral mediated gene transfer in chronic myelogenous leukaemia. Br J Haematol 1994; 87: 308-316.
66. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM. Single base discrimination for ribonuclease H dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 1995; 23: 954-961.
67. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilisation of human leukaemia cells with streptolysin O. Antisense Res Dev 1995; 5: 13-21.
68. Broughton CM, Spiller DG, Pender N, Komorovskaya M, Grzybowski J, Giles RV, Tidd DM, Clark RE. Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients. Leukemia 1997; 11: 1435-1441.
69. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
70. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
71. Editorial. Chronic myeloid leukaemia: potential for antisense therapy. Lancet 1992; 340: 1262-1263.
72. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukaemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 1991; 253: 562-565.
73. Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J. Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995; 23: 1606-1611.
74. Smetsers TFCM, Skorski T, van de Locht LTF, Wessels HMC, Pennings AHM, De Witte T, Calabretta B, Mensink EJBM. Antisense bcr-abl oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994; 8: 129-140.
75. De Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 1993; 12: 261-265.
76. De Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 1997; 11: 811-819.
77. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukaemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
78. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukaemia. Blood 1994; 83: 2038-2044.
79. Smetsers TFCM, van de Locht LTF, Pennings AHM, Wessels HMC, de Witte TM, Mensink EJBM. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular BCR-ABL protein levels. Leukemia 1995; 9: 118-130.
80. Dhut S, Chaplin T, Young BD. BCR-ABL and BCR proteins; biochemical characterisation and localisation. Leukemia 1990; 4: 745-750.
81. Croce CM, Nowell PC. Molecular basis of human B cell neoplasia. Blood 1985; 65: 1-7.
82. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo R, Croce CM. Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
83. Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada T, Finan J, Emanuel BS, Nowell PC, Croce CM. Deregulation of c-myc by translocation of the T-cell receptor in T-cell leukaemias. Science 1986; 232: 884-886.
84. Chang H, Benchimol S, Minden MD, Messner HA. Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood 1994; 83: 452-459.
85. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 1994; 84: 883-888.
86. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
87. Weisenburger DD, Armitage JO. Mantle cell lymphomal - an entity comes of age. Blood 1996; 87: 4483-4494.
88. Sawyers CL, Callahan W, Witte ON. Dominant negative myc blocks transformation by abl oncogenes. Cell 1992; 70: 901-910.
89. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of bcr-abl point mutants with c-myc. Science 1994; 264: 424-426.
90. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387: 422-426.
91. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1982; 304: 596-602.
92. Kohl NE, Ruley HE. Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene 1987; 2: 41-48.
93. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL-2. Proc Natl Acad Sci USA 1995; 92: 5287-5291.
94. Beimling P, Benter T, Sander T, Moelling K. Isolation and characterisation of the human cellular MYC gene product. Biochemistry 1985; 24: 6349-6355.
95. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukaemia HL60 cell proliferation and c-MYC protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-MYC mRNA. Proc Natl Acad Sci USA 1988; 85: 1028-1032.
96. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM. A c-MYC antisense oligodeoxyribonucleotide inhibits entry into S phase but not progression from G0 to G1. Nature 1987; 328: 445-449.
97. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-MYC mRNA inhibits proliferation of HL60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988; 8: 963-973.
98. McManaway ME, Neckers LM, Loke SL, Al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, McGrath IT. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808-811.
99. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
100. + cells present in autologous transplants of chronic: myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
101. Letheby BA, Jackson JD, Whalen VL, Bishop MR, Iversen PL, Sharp JG, Kessinger A, Armitage JO, Warkentin PI. Ex vivo treatment of normal peripheral blood-derived progenitor cells with antisense bcr-abl oligonucleotides. Exp Hematol 1994; 22: 778 (Abstr.).
102. Keating A, Wang XH, Laraya P. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83: 1744-1749.
103. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, Jones RJ. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993; 81: 2898-2902.
104. Gewirtz AM, Anfossi G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-MYB. Science 1989; 245: 180-183.
105. Oehler T, Arnold H, Biedenkapp H, Klempnauer KH. Characterization of the v-myb binding domain. Nucleic Acids Res 1990; 18: 1703-1710.
106. Weber BL, Westin EH, Clarke MF. Differentiation of mouse erythroleukaemia cell enhanced by alternatively spliced c-myb mRNA. Science 1990; 249: 1291-1293.
107. Mucenski ML, McLain K, Kier AB, Swerdlow AH, Schreiner CM, Miller TA, Peitryga DW, Scott WJ Jr, Potter SS. A functional c-myb gene is required for normal fetal hepatic hematopoiesis. Cell 1991; 65: 677-689.
108. Calabretta B, Sims RB, Valiteri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM. Normal and leukaemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-MYB antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991; 88: 2351-2355.
109. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McClave P, Gewirtz AM. Acute and chronic phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-MYB antisense oligodeoxynucleotides. Blood 1992; 79: 1956-1961.
110. Gewirtz AM, Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988; 242: 1303-1306.
111. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ. Oligodeoxynucleotide therapeutics for human myelogenous leukaemia: interim results. Blood 1996; 88 (Suppl. 1): 270a (Abstr.).
112. de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukaemia in advanced phase. Blood 1998; 91: 3156-3162.
113. Sun J, Zhou S, Wu B, Liu Q, Feng R, Liu X. Autologous bone marrow translantation after in vitro purging with BCR/ABL antisense for CML patients. Exp Hematol 1997; 25: 812 (Abstr.).
114. Clark RE, Grzybowski J, Broughton CM, Pender N, Spiller DG, Brammer C, Giles RV, Tidd DM. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery tor purging autografts in chronic myeloid leukaemia. Bone Marrow Transplant 1999; 23: 1303-1308.
115. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B. Suppression of Philadelphial leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994; 91: 4504-4508.
116. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukaemia blast crisis in SCID mice. Blood 1996; 88: 1005-1012.
117. Cotter FE, Johnson P, Hall P, Pocock C, al-Mahdi N, Cowell JK, Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-3055.
118. Webb A, Cunningham D, Cotter F, Clarke PA, Di Stefano F, Ross P, Corbo M, Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
119. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in haematological malignancies. J Clin Oncol 1996; 14: 1320-1326.
120. Barton C, Lemoine N. Antisense oligonucleotides targeting p53 (Better). J Clin Oncol 1997; 15: 408.
121. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-387.
122. Morgan R, Edge M, Colman A. A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligonucleotides. Nucleic Acids Res 1993; 21: 4615-4620.
123. McKay RA, Cummins LL, Graham MJ, Lesnik EA, Owens SR, Winniman M, Dean NM. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res 1996; 24: 411-417.
124. Altmann K-H, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, Nicklin P. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 1996; 24: 630-636.
125. Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, Thomson SA, Pipe A, Hassman F, Bisi JE, Froehler BC, Matteucci MD, Wagner RW, Noble SA, Babiss LE. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res 1995; 23: 1197-1203.
126. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333-335.
127. Nielson PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-1500.
128. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 1993; 365: 566-568.
129. Antivirals Technical Report No. 2. Antisense Research and Development 3: after p153, 1993.
130. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996; 6: 267-272.
131. Giles RV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analogue induces mis-splicing of C-MYC mRNA. Antisense Res Dev 1999; 9: 213-220.
132. Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassaemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 1996; 93: 12840-12844.
133. Kang SH, Cho MJ, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 1998; 37: 6235-6239.